A STUDY ON SERUM FIBRINOGEN AS AN INDEPENDENT PREDICTOR OF MAJOR ADVERSE CARDIAC EVENTS (MACE) IN KNOWN DIABETIC CORONARY ARTERY DISEASE PATIENTS

Dissertation submitted to
THE TAMILNADU Dr. M.G.R MEDICAL UNIVERSITY
CHENNAI

In partial fulfillment of the regulations
For the award of the degree

M.D GENERAL MEDICINE
BRANCH -1

GOVT STANLEY MEDICAL COLLEGE
& HOSPITAL, CHENNAI -1

APRIL 2013
CERTIFICATE

This is to certify that this dissertation entitled “A STUDY ON SERUM FIBRINOGEN AS AN INDEPENDENT PREDICTOR OF MAJOR ADVERSE CARDIAC EVENTS (MACE) IN KNOWN DIABETIC CORONARY ARTERY DISEASE PATIENTS” submitted by Dr. AMUDHAN .M to The Tamil Nadu Dr. M.G.R Medical University is in partial fulfillment of the requirement of the award of M.D DEGREE [GENERAL MEDICINE] BRANCH 1 and is a bonafide research work carried out by him under direct supervision and guidance.

Prof. K.MADHAVAN, M.D.,
Professor of medicine,
Department of General medicine,
Stanley Medical College and Hospital,
Chennai – 600001

Prof. S.MAHESH KUMAR, M.D.,
Professor and HOD,
Department of General medicine,
Stanley Medical College and Hospital,
Chennai – 600001

Dr. S.GEETHALAKSHMI M.D., Ph.D.,
Dean
Govt. Stanley Medical College
Chennai – 600001
DECLARATION

I, Dr. AMUDHAN .M, solemnly declare that the dissertation titled “A STUDY ON SERUM FIBRINOGEN AS AN INDEPENDENT PREDICTOR OF MAJOR ADVERSE CARDIAC EVENTS IN KNOWN DIABETIC CORONARY ARTERY DISEASE PATIENTS”, is a bonafide work done by me at Govt. Stanley Medical College and Hospital from april 2012 to november 2012 under the guidance and supervision of my unit chief, Prof. Dr. K. Madhavan, M.D., Professor of Medicine, This dissertation is submitted to The Tamilnadu Dr.M.G.R. Medical University towards the partial fulfilment of the requirements of M.D. Branch I,General medicine degree examination.

PLACE:

DATE: Dr. M. AMUDHAN
ACKNOWLEDGEMENT

My sincere thanks to Dr. S. GEETHALAKSHMI, MD., Ph.D., the Dean, Govt. Stanley Medical College, Prof. S. MAHESH KUMAR M.D., Professor and HOD, Department of General medicine, Govt. Stanley Medical College and Hospital for permitting me to undertake and successfully complete this study in Govt. Stanley Medical College and Hospital, Chennai.

I am extremely grateful to our unit Chief, Prof. K. MADHAVAN M.D., who has been the main pillar for this study, for his valuable guidance and encouragement throughout this study.

I would like to thank my assistant professors, Dr. GEETHA. M.D., for her valuable suggestions and help in completing this dissertation.

I am particularly thankful to my fellow postgraduate colleague Dr. SUBBURAJI and other fellow post graduates, for their valuable support in the time of need throughout this study.

Last but not the least I would like to thank my patients with gratitude for their cooperation during the study.
INTRODUCTION

Diabetes Mellitus is one of the leading cause of morbidity and mortality worldwide. Its Prevalence is gearing up at a faster pace all over the world especially in developing countries like India.

It is the most important risk factor in the pathogenesis of Acute Coronary syndrome. Coronary artery disease is one of the most common Macro vascular complications of Diabetes, especially Type 2 diabetes. It is the leading cause of mortality and morbidity in diabetes.

In addition, diabetic patients are likely to have Poor treatment outcome compared with non-Diabetic controls. Its occurrence is increasing in younger age group, causing premature coronary artery disease and premature death.
Your digital receipt

This receipt acknowledges that Turnitin received your paper. Below you will find the receipt information regarding your submission.

| Parameter          | Information                                                      |
|--------------------|------------------------------------------------------------------|
| Paper ID           | 293437952                                                        |
| Paper title        | a study on serum fibrinogen as an independent predictor of major adverse cardiac events in diabetic coronary artery disease patients |
| Assignment title   | Medical                                                          |
| Author             | Amuthan 20101051 M.D. General Medicine                            |
| E-mail             | dramudhan85@gmail.com                                             |
| Submission time    | 24-Dec-2012 04:27AM                                               |
| Total words        | 12061                                                            |

First 100 words of your submission

A STUDY ON SERUM FIBRINOGEN AS AN INDEPENDENT PREDICTOR OF MAJOR ADVERSE CARDIAC EVENTS (MACE) IN KNOWN DIABETIC CORONARY ARTERY DISEASE PATIENTS
Dissertation submitted to THE TAMILNADU Dr. M.G.R MEDICAL UNIVERSITY CHENNAI in partial fulfillment of the regulations For the award of the degree M.D GENERAL MEDICINE BRANCH -1 GOVT STANLEY MEDICAL COLLEGE & HOSPITAL, CHENNAI-1 APRIL 2013 CERTIFICATE This is to certify that this dissertation entitled "A STUDY ON SERUM FIBRINOGEN AS AN INDEPENDENT PREDICTOR OF MAJOR ADVERSE CARDIAC EVENTS (MACE) IN KNOWN DIABETIC CORONARY ARTERY DISEASE PATIENTS" submitted by Dr. AMUDHAN M to The Tamil Nadu Dr. M.G.R Medical University is in partial fulfillment...
LIST OF ABBREVIATIONS

T1DM : TYPE 1 DIABETES MELLITUS
MODY  : MATURITY ONSET DIABETES OF YOUNG
HNF   : HEPATOCYTE NUCLEAR TRANSCRIPTION FACTOR
IPF   : INSULIN PROMOTER FACTOR
DNA   : DEOXY RIBO NUCLEIC ACID
ATP   : ADENOSINE TRI PHOSPHATE
NK    : NATURAL KILLER
PPAR  : PEROXISOME PROLIFERATOR ACTIVATOR RECEPTOR
IRS   : INSULIN RECEPTOR SUBSTRATE
TNF α : TUMOUR NECROSIS FACTOR α
PAI   : PLASMINOGEN ACTIVATOR INHIBITOR
IR    : INSULIN RESISTANCE
TGF β : TISSUE GROWTH FACTOR β
ACEI  : ANGIOTENSIN CONVERTING ENZYME INHIBITOR
NCS   : NERVE CONDUCTION STUDY
MI    : MYOCARDIAL INFARCTION
CT    : COMPUTER TOMOGRAPHY
t-PA   : TISSUE PLASMINOGEN ACTIVATER
BMI   : BODY MASS INDEX
WBC   : WHITE BLOOD CELL
# CONTENTS

| Sl.No | TITLE                                    | PAGE NO |
|-------|------------------------------------------|---------|
| 1.    | INTRODUCTION                             | 1       |
| 2.    | AIM OF THE STUDY                         | 3       |
| 3.    | REVIEW OF LITERATURE                     | 4       |
| 4.    | MATERIALS AND METHODS                    | 43      |
| 5.    | RESULTS                                  | 49      |
| 6.    | DISCUSSION                               | 70      |
| 7.    | SUMMARY AND CONCLUSION                   | 74      |
| 8.    | ANNEXURE                                 |         |
|       | ➢ BIBLIOGRAPHY                           |         |
|       | ➢ PROFORMA                               |         |
|       | ➢ MASTER CHART                           |         |
|       | ➢ KEY TO MASTER CHART                    |         |
|       | ➢ ETHICAL COMMITTEE APPROVAL ORDER       |         |
| S.NO | TABLE                                                                 | PAGE.NO |
|------|----------------------------------------------------------------------|---------|
| 1    | Groupwise distribution of study population                          | 51      |
| 2    | Prevalence of MACE                                                 | 52      |
| 3a   | Relation between MACE and age                                      | 53      |
| 3b   | Statistical age group comparison                                   | 54      |
| 4    | Relation between MACE and sex                                      | 55      |
| 5    | Relation between MACE and Diabetes duration                        | 56      |
| 6    | Relation between MACE and FBS                                      | 57      |
| 7    | Relation between MACE and PPBS                                     | 58      |
| 8    | Relation between MACE and Glycemic control                         | 59      |
| 9    | Relation between serum Fibrinogen and Age                          | 60      |
| 10   | Relation between serum Fibrinogen and sex                          | 61      |
| 11   | Relation between serum Fibrinogen and duration of Diabetes         | 62      |
| 12a  | Relation between serum Fibrinogen and FBS                          | 63      |
| 12b  | Statistical comparison between Fibrinogen and FBS                  | 63      |
| 13a  | Relation between serum Fibrinogen and PPBS                         | 65      |
| 13b  | Statistical comparison serum Fibrinogen and PPBS                    | 65      |
| 14   | Relation between serum Fibrinogen and Glycemic control             | 67      |
| 15a  | Relation between serum Fibrinogen and MACE                         | 68      |
| 15b  | Statistical comparison between serum Fibrinogen and MACE           | 68      |
## LIST OF CHARTS

| S.NO | CHART               | PAGE.NO |
|------|---------------------|---------|
| 1    | Age distribution    | 49      |
| 2    | Gender distribution | 50      |
INTRODUCTION

Diabetes Mellitus is one of the leading cause of morbidity and mortality worldwide. Its Prevalence is gearing up at a faster pace all over the world especially in developing countries like India.

It is the most important risk factor in the pathogenesis of Acute Coronary syndrome. Coronary artery disease is one of the most common Macro vascular complications of Diabetes, especially Type 2 diabetes. It is the leading cause of mortality and morbidity in diabetes.

In addition, diabetic patients are likely to have Poor treatment outcome compared with non-Diabetic controls. Its occurrence is increasing in younger age group, causing premature coronary artery disease and premature death inflicting economic burden to the family and to the society.

Recently studies are focussing on serum Fibrinogen and its role in the pathogenesis of Coronary artery disease in Diabetes. Fibrinogen being an acute phase reactant is
also a pro-coagulant. It plays a major role in coagulation of blood. It has a significant role in Athero-thrombosis. Hence its role in adverse cardiac events in Diabetics and its prognostic value is currently the study of interest.
AIMS & OBJECTIVES

- To determine the concentration of Fibrinogen in diabetic CAD and its causal relationship to adverse cardiac events.

- To ascertain serum fibrinogen’s predictive value of major adverse cardiac events in Diabetic CAD.

- To ascertain the prognostic value of serum fibrinogen in Diabetic patients presenting with subsequent major adverse cardiac events.

- To evaluate the relation between serum Fibrinogen and other factors that cause adverse cardiac events.
REVIEW OF LITERATURE

DIABETES MELLITUS

It is a metabolic disorder of varied aetiology characterised by chronic hyperglycaemia and altered metabolism of carbohydrates, protein and fat leading to vascular syndrome affecting small and large sized blood vessels. It results from

- Defective insulin secretion
- Defective insulin action
- Both

EPIDEMIOLOGY

The prevalence of diabetes is increasing worldwide and in particular, developing countries like India. It has now become an important public health problem in India. With this pace, the Diabetic population in India would be around 70 million by 2030. At present, India heads the list of countries with highest population of Diabetics. The prevalence of DM is progressively stepping up and in particular T2DM prevalence is stepping up with rapid phase due to following factors
- Social habits leading to obesity
- Idle nature of daily routine activities
- Industrialisation
- Ageing of people
- Geographic status
- Genetic factors
- Environmental factors
**CLASSIFICATION**

| I. Type 1 diabetes (β cell destruction, usually leading to absolute insulin deficiency) |
| --- |
| A. Immune-mediated |
| B. Idiopathic |

| II. Type 2 diabetes (may range from predominantly insulin resistance with relative insulin deficiency to a predominantly insulin secretory defect with insulin resistance) |
| --- |
| A. Genetic defects of cell function characterized by mutations in: |
| 1. Hepatocyte nuclear transcription factor (HNF) 4 (MODY) |
| 2. Glucokinase (MODY 2) |
| 3. HNF-1 (MODY 3) |
| 4. Insulin promoter factor-1 (IPF-1; MODY 4) |
| 5. HNF-1 (MODY 5) |
| 6. NeuroD1 (MODY 6) |
| 7. Mitochondrial DNA |
| 8. Subunits of ATP-sensitive potassium channel |
| 9. Pro-insulin or insulin conversion |

| B. Genetic defects in insulin action |
| --- |
| 1. Type A insulin resistance |
| 2. Leprechaunism |
| 3. Rabson-Mendenhall syndrome |
| 4. Lipodystrophy syndromes |

| C. Diseases of the exocrine pancreas—pancreatitis, pancreatectomy, neoplasia, cystic fibrosis, |
hemochromatosis, fibrocalculous pancreatopathy, mutations in carboxyl ester lipase

D. Endocrinopathies—acromegaly, Cushing's syndrome, glucagonoma, pheochromocytoma, hyperthyroidism, somatostatinoma, aldosteronoma

E. Drug- or chemical-induced—Vacor, pentamidine, nicotinic acid, glucocorticoids, thyroid hormone, diazoxide, beta-adrenergic agonists, thiazides, hydantoin, alpha-interferon, protease inhibitors, anti-psychotics (atypicals and others), asparaginase, epinephrine

F. Infections—congenital rubella, cytomegalovirus, coxsackie

G. Uncommon forms of immune-mediated diabetes—"stiff-person" syndrome, anti-insulin receptor antibodies

H. Other genetic syndromes sometimes associated with diabetes—Down's syndrome, Klinefelter's syndrome, Turner's syndrome, Wolfram's syndrome, Friedreich's ataxia, Huntington's chorea, Laurence-Moon-Biedl syndrome, myotonic dystrophy, porphyria, Prader-Willi syndrome

IV. Gestational diabetes mellitus (GDM)
Inspite of ongoing research and advent of newer Antidiabetic drugs, Diabetes is still considered high risk, causing high occurrence of Coronary artery disease and cerebrovascular accidents.\(^2,3,4\)

Incidence of microvascular complication such as Retinopathy, neuropathy and Nephropathy are also much higher in Diabetes.\(^5,6,7\)

**TYPE I DIABETES:**

Various genetic factors, environmental and immunological components contribute to its development causing ultimately, pancreatic beta cell damage and absolute insulin deficiency as a result.

The immune mechanism that underlies the development of T1DM is auto immunity mediated by T-cell, where autoantibodies attacks beta cells of pancreatic islets and destroys them.

In most individual there is autoimmune destruction of beta cells and may have evidence to it, in form of
autoantibodies. Some may not have evidence or markers for autoimmune process and they might have developed insulin deficiency due to idiopathic or non-immune mechanism.

The Autoimmune pancreatic pathology in development of T1DM is evident from pathological changes in pancreas of persons with impaired fasting glucose and impaired glucose tolerance. It is characteristically shows inflammatory cell infiltration of Islet cell such as:

- Activated macrophages
- Helper T cells
- Cytotoxic T cells
- Suppressor T cells
- NK Cells
- B Lymphocytes

- Selective destruction of Beta cells sparing cells that secrete Glucagon and other hormones.

- Patchy lesion with infiltrated lobules amidst unaffected lobules.
T1DM may co-exist with Auto immune diseases such as

- Autoimmune thyroiditis
- Coeliac disease
- Addisons disease
- Pernicious anaemia
- Vitiligo

Which further support pathological mechanism of Autoimmunity in the etiopathogenesis of T1DM.

**Clinical course of type I DM:**

At birth, all individuals have normal beta cell mass, later as age advances they lose their beta cell mass due to autoimmune mechanism, which is initiated by some environmental or infectious stimuli, that demands increased insulin requirement

Until 70% - 80% of beta cells are destroyed, the individuals will be asymptomatic. As age and immunological processes advances, the percentage of destroyed beta cells reach a point at which the remaining viable beta cells are not enough to tolerate glucose load and they exhibit the clinical signs and symptoms.
Rate of destruction of beta cell mass varies with individuals.

**TYPE II DIABETES:**

Two important pathological events that contributes to development of T2DM are

- Insulin resistance
- Defective insulin secretion

The presence of these two events may not be sufficient to cause T2DM unless there is extensive beta cell dysfunction. This has led to the observation, where Genetics play a contributory role in the pathogenesis of T2DM.

Though Genetic factor is considered a special position in the etiology, the chance that a patient with Genetic susceptibility to develop Diabetes is largely decided by other factors such as
In fact insulin resistance occurs long before defective insulin secretion. T2DM manifests only after insulin secretion becomes defective.

It has a significant genetic association as evidenced by prevalence of insulin resistance in non-diabetic close relatives of T2DM patients. Other than genetic factors there are other factors that contribute to its development.

- Obesity
- Sedentary lifestyle
- Food habits
- The culprit genes are not yet completely identified. But recent studies have identified some associate genes such as
- Transcription factor 7-like 2 gene

Genetic polymorphism of genes encoding,

- PPAR-γ
- Zinc transporter
  - IRS
  - Calpain10

are associated with T2DM.

1DIAGNOSTIC CRITERIA

- Symptoms of diabetes plus random blood glucose concentration of 11.1 mmol/L (200 mg/Dl or more) or
- Fasting plasma glucose 7.0 mmol/L (126 mg/dL or more) or
- Two-hour plasma glucose 11.1 mmol/L (200 mg/dL or more) during an oral glucose tolerance test using 75g anhydrous glucose
- A1C > 6.5%

Diabetic men have two times the risk of adverse cardiovascular events than non-diabetic control group. In women, the risk is three times in diabetic group than non-diabetic control group.
Cardiovascular risk factors such as obesity and hypertension are co-existing in a higher frequency and level in diabetic than non-diabetic.\textsuperscript{5,9-16} This contributes to the increased risk and occurrence of adverse cardiovascular events in Diabetics than control group with conventional risk factor alone.

In addition to this, there is a significant difference in the serum levels of HDL, LDL and VLDL between Diabetics and Non Diabetic group, where HDL is low and LDL, VLDL are high in Diabetics when compared to non diabetics in whom HDL is higher and LDL, VLDL is lower than the Diabetic group.\textsuperscript{2}

There are still other studies which confers only little correlation between the quantitative status of the risk factor and the occurrence of Adverse cardiac events, which has individual variation both in diabetic and non-diabetic.\textsuperscript{2}
DIABETES & INFLAMMATION

Inflammation plays an important role in the evolution of T2DM. Diabetes is now linked with chronic inflammatory state and this has been attributed to abnormal lipid metabolism\(^1\).

Insulin mediates its action by binding to insulin receptor in the surface of the Insulin responsive cells. The receptor in turn gets phosphorylated by itself and insulin receptor substrate family. This marks the initiating event in downstream signaling pathway.

Recent studies have shown some metabolic components involved in interference of signalling pathway. For instance in obesity metabolic overload puts endoplasmic reticulum in an incapacitant state. This burden, that is inflicted upon endoplasmic reticulum, activates inflammatory signal pathway and finally leading to Insulin resistance.\(^ {17,18,19} \)
Another mechanism by which metabolic factor involves in this inflammatory pathway is increased production of Reactive oxygen species by mitochondria in obesity leading to enhanced activation of inflammatory pathway.\textsuperscript{20,21}

Obesity and diabetes share common features of insulin resistance. In obesity there will be excessive accumulation of saturated fat in white adipose tissue resulting in increased synthesis and release of saturated fatty acids and TNF-\(\alpha\).

High level of free fatty acid and TNF-\(\alpha\) activates inhibitory phosphorylation of serine residues of IRS – I\textsuperscript{22,23}. This inhibits insulin stimulated tyrosine phosphorylation of IRS-I to interact with insulin receptor. This results in inhibition of insulin action\textsuperscript{22,24,25}.

Development of insulin resistance, T2DM and cardiovascular disease to a great extent are mediated by inflammatory processes. This is evident from high levels of circulating inflammatory markers such as CRP, cytokines,
fibrinogen, IL-6, IL-8, PAI & TNF-α seen in T2DM patients\textsuperscript{21}.

Visceral obesity, which is common in diabetes leads to excess adipose tissue producing various adipokines including inflammatory cytokines. These inflammatory agents are a key component to the development of IR, obesity, diabetes\textsuperscript{21}, atherosclerosis, heart disease and fatty liver.

**DIABETES COMPLICATIONS**

Prolonged hyperglycaemia seen in diabetic is a key feature which poses deleterious effect in the human body.

Its adverse effects affecting the vascular anatomy are main events contributing to micro vascular and macro vascular diseases.

**COMPLICATIONS OF DIABETES :**

- *Acute*
  
  Diabetic ketoacidosis
  
  Hyperglycemic hyperosmolar state
Hypoglycemia
Diabetic coma

- **Chronic**

  Microvascular:
  - Diabetic cardiomyopathy
  - Diabetic nephropathy
  - Diabetic neuropathy
  - Diabetic retinopathy

  Macrovascular disease:
  - Coronary artery disease
  - Diabetic myonecrosis
  - Peripheral vascular disease
  - Stroke

Both Microvascular and Macrovascular:
- Diabetic sexual dysfunction
MICROVASCULAR COMPLICATION :

Pathogenesis

The development of micro vascular complication depends on degree and duration of hyperglycaemia. Four possible mechanismshave been postulated. They are

- Metabolic overload in form of excess Sorbitol and other Polyols within the endothelial layer.
- Increased production of Prostaglandin products as a result of up regulation of Protein kinase C.
- Nonenzymatic glycosylation of protein leading to increased production of advanced glycation end products and thereby increased production of TGF β.

Consequently all these factors lead to Glucose mediated oxidative damage.

However there are still some studies which contradict the role of Hyperglycaemia in the aetiopathogenesis of diabetic complications. This fact was arrived from a study, where 40 % of the Diabetics even after meticulous optimal Glycaemic status develop Neuropathy eventually.\textsuperscript{27}
This holds the same for development of Nephropathy, where some study shows progression to Nephropathy despite good Glycaemic control.\textsuperscript{28}

MICROVASCULAR COMPLICATIONS

Diabetic retinopathy

It is the commonest micro vascular complication. Degree of hyperglycaemia and its duration predicts the risk of developing retinopathy. Development of diabetic retinopathy in T2DM may also require other risk factor such as hypertension.

The process of diabetic retinopathy starts well before the diagnosis of T2DM was made in T2DM patient\textsuperscript{1}.

Proposed mechanism

Increased concentration of Sorbitol, which is a glucose alcohol derived from Glucose by POLYOL pathway is one mechanism. Here high sorbitol concentration lead to osmotic stress which is thought to be the basic mechanism in most micro vascular complication including Diabetic Retinopathy.
Other postulated mechanisms are

- Oxidative stress by production of free radicals and reactive Oxygen species

Increased production of

- Growth factors such as Vascular Endothelial derived Growth factor.
- Growth Hormone
- TGF β
- Product of advanced glycosylated end product

The role of Vascular endothelial growth factor\textsuperscript{29,30,31} and TGFβ are also implicated as evidenced by certain studies.

Diabetic retinopathy can have major impact on the patient to the extent of blindness, especially if proliferative retinopathy sets in. so close monitoring for diabetic retinopathy is needed.
Diabetic nephropathy

It is characterised by proteinuria of more than 500ms in 24 hours in diabetic patients. Usually it follows micro albuminuria, where there is excretion of albumin of 30-300mg/day.

Micro albuminuria starts well early in the clinical span of T2DM. so it is prudent to screen for micro albuminuria very early, as 7% of T2DM patients are positive for micro albuminuria at diagnosis.

If no intervention has been taken during the time of micro albuminuria, the disease will worsen to proteinuria and finally end in diabetic nephropathy. ACEI therapy retards the progression to nephropathy in T2DM and prevent them in type I DM\textsuperscript{32,33}. So ACEI is considered in the first line management of micro albuminuria, even in normotensive patient\textsuperscript{33}.
Diabetic neuropathy

It is often unrecognised micro vascular complication of diabetes.

Peripheral neuropathy of diabetes is often a diagnosis of exclusion. Numerous works up is necessary to arrive at the diagnosis of diabetic neuropathy.

In some people often present with foot ulcer before diagnosis is made. It accounts for more than 80% of amputation\(^34\). Exact mechanism by which diabetes causes neuropathy is not known, but the risk of diabetic neuropathy has a linear relationship with degree and duration of diabetes.

Distal symmetric sensorimotor polyneuropathy is the commonest type of neuropathy. Patient gives a history of tingling, burning pain or numbness. There is involvement of posterior column as evidenced by hypoaesthesia to total sensory loss to light touch, temperature and vibration. Ankle reflex is absent\(^34\). Diabetes with sensory loss to 10-g monoplanes are more prone for foot ulcer.
Other types

- Pure sensory neuropathy
- Mononeuropathies
- Diabetic amyotrophy
- Autonomic neuropathy

NCS shows reduction in amplitude and conduction of nerve impulse.

Differential diagnosis

- Hypothyroidism
- Vitamin B12 deficiency
- Chronic inflammatory polyneuropathy
- Uraemia

Glycaemic control is main treatment strategy to prevent and to retard the progression of diabetic neuropathy. Other contributing factors such as high blood pressure and dyslipidemia should be corrected.
MACROVASCULAR COMPLICATION

The key underlying pathological mechanism that leads to the development of macro vascular disease is atherosclerosis.

The process involves injury to endothelium by chronic inflammatory process causes deposition and aggregation of oxidised lipids in LDL within the endothelial wall. This followed by monocyte infiltration and macrophage transformation. This process along with oxidised lipid lead to foam cell generation. Foam cell formation is followed by proliferation of macrophage and attraction of T-lymphocytes which cause increased smooth muscle proliferation and collagen deposition.

Final product is atheromatous plaque rich in lipids with a fibrous envelope. Rupture of this plaque causes acute vascular occlusion. Diabetes have high incidence of plaque ulceration and intra coronary thrombus formation.
Other factor that contribute to vasculopathy are

- Increased platelet adhesion
- Hyper coagulopathy due to increased fibrinogen.
- Increased free radical formation & platelet aggregation.
- Increased PAI -1

So combined additive effects of pronounced coagulability and defective fibrinolysis cause the incidence of vascular obstruction and major adverse cardiac events to be higher in diabetes, especially T2DM patients [36]

Metabolic syndrome, comprising early spectrum of Diabetes as one of its components poses a major risk factor for Atheromatous vascular disease.

It is a group of adverse medical events which when co-exist together enhances the occurrence of adverse cardiac events in addition to Diabetes. It is also known as
- Cardiometabolic syndrome
- Syndrome X
- Insulin resistant syndrome
- Reaven’s syndrome

Other conventional risk factors such as smoking, obesity, Hypertension, Microalbuminuria, Hypercholesterolemia and increased lipoprotein (a) may coexist or some can be a consequent to it.

The number of risk factors in a person has a linear relationship with chance of developing major adverse cardiac events. In the presence of these factors Diabetes magnifies the adverse events caused by them.

Coronary heart disease is the commonest macro vascular complication in T2DM.

Risk of Myocardial infarction in a person with Diabetic is same as that of a Non Diabetic with prior history of Myocardial infarction. Hence diabetes is considered as angina equivalent. Presence of diabetes
confers a risk of MI equivalent to the risk of MI in a non-diabetic with past history of MI.

CORONARY ARTERY DISEASE

It is the most common heart disease. It is caused by narrowing of coronary arteries by atherosclerotic process. It is a chronic pathological process which begins in early life and manifests in early or late adulthood.

“Atherosclerosis” literally refers to localized aggregation of lipids and this affects the intimal layer of epicardial coronary artery thereby causing thickening of intimal layer.

Large and medium sized arteries are commonly involved. Atherosclerosis initiates inflammatory process in the vessel wall and cause endothelial dysfunction. This attracts lipids, cholesterol, inflammatory cells and calcium within the intimal layer of blood vessel.

This leads to the genesis of plaque, which is made up of fat, cholesterol, calcium deposits and inflammatory
cells. It starts as fatty streak which later develops into fibrous plaque, a lipid rich core composed of inflammatory cells, smooth muscle cells and cellular debris within it.

In patients with diabetes the inflammatory changes are marked. The degree of lipid composition in the plaque is more in diabetic CAD than non-diabetic CAD. Also there is increased inflammatory cell infiltration and thrombosis in them when compared to non-diabetics with coronary artery disease\textsuperscript{37}.

These atheromatous plaque accumulate progressively and in advanced stage of the process, it causes luminal obstruction. The hemodynamics of the coronary blood flow is affected and there is reduced oxygen supply to the organs. Myocardial oxygen supply cannot meet increasing demands during exertion initially.

There is enough evidence to suggest high incidence of coronary artery disease in patients with conventional risk factors\textsuperscript{38} such as
• Smoking
• obesity
• Dyslipidemia (increased LDL)
• Hyperfibrinogenemia & increased factor VII\textsuperscript{39}
• Hyperlipoprotein (a)\textsuperscript{40}
• Hepatic lipase\textsuperscript{41}
• Advancing age

The role of alcohol in the causation of atherosclerotic coronary artery disease is controversial. Though alcohol causes altered metabolism, a mild to moderate intake of alcohol has been associated with decreased incidence of adverse cardiac events such as CAD\textsuperscript{42}
Micrograph of a coronary artery with marked atherosclerosis and luminal narrowing.
### Pathophysiology of Atherosclerosis

| NOMENCLATURE AND MAIN HISTOLOGY | SEQUENCES IN PROGRESSION OF Atherosclerosis | EARLIEST ONSET | MAIN GROWTH MECHANISM | CLINICAL COLLERATION |
|---------------------------------|--------------------------------------------|----------------|------------------------|----------------------|
| **Initial lesion**              |                                            | from first decade | growth mainly by lipid addition | clinically silent |
| • histologically "normal"       |                                            |                |                        |                      |
| • macrophage infiltration       |                                            |                |                        |                      |
| • isolated foam cells           |                                            |                |                        |                      |
| **Fatty streak**                |                                            | from third decade |                        | clinically silent or overt |
| mainly intracellular lipid      |                                            |                |                        |                      |
| accumulation                     |                                            |                |                        |                      |
| **Intermediate lesion**         |                                            | from fourth decade | increased smooth muscle and collagen increase | clinically silent or overt |
| • intracellular lipid accumulation |                                        |                |                        |                      |
| • small extracellular lipid pools|                                          |                |                        |                      |
| **Atheroma**                    |                                            |                |                        |                      |
| • intracellular lipid accumulation |                                        |                |                        |                      |
| • core of extracellular lipid   |                                            |                |                        |                      |
| **Fibroatheroma**               |                                            |                |                        |                      |
| • single or multiple lipid cores |                                          |                |                        |                      |
| • fibrotic/calcific layers      |                                            |                |                        |                      |
| **Complicated lesion**          |                                            |                |                        |                      |
| • surface defect                |                                            |                |                        |                      |
| • hematoma-hemorrhage           |                                            |                |                        |                      |
| • thrombosis                    |                                            |                |                        |                      |
The role of alcohol in the causation of atherosclerotic coronary artery disease is controversial. Though alcohol causes altered metabolism, a mild to moderate intake of alcohol has been associated with decreased incidence of adverse cardiac events such as CAD.⁴²

Aerobic exercise reduces the risk of coronary artery disease. This is supported by some studies where reduction in the serum level of lipids and inflammatory markers such as C-reactive protein, fibrinogen were observed after an aerobic exercise program.⁴³

The pathological mechanisms by which some risk factors lead to coronary artery disease are mediated through fibrinogen in common. This is evidenced by some studies which showed higher level of fibrinogen in smokers⁴⁴ and in diabetics⁴⁵.
CLINICAL MANIFESTATION:

Coronary artery disease has diverse clinical symptoms and signs\textsuperscript{46} ranging from stable angina to sudden death. Depending upon the anatomical viability of atheromatous plaque.

Chest pain with diaphoresis is the most common presentation. A typical anginal pain is that of a retrosternal pain with a sense of heaviness, brought on exertion radiating to the neck, lower jaw, left shoulder, left arm or epigastrium and is relieved by rest and nitrates in stable angina.

But however this typical symptom need not be present always. They may have other symptoms which appear unrelated. They are termed angina equivalents.

Anginal equivalents are\textsuperscript{46}

- Dyspnea
- Diaphoresis
- Fatigue
- Atypical chest pain
INVESTIGATION:

Patients basic investigations such as complete blood count, Thyroid function test, Fasting lipid profile and Glycemic status should be ascertained by fasting and postprandial blood sugar. Patients should be subjected to ECG both at rest and during stress. Cardiac evaluation using ECHO should be done, Thallium scintiography and CT Coronary Angiogram should be done where feasible.

DIABETES AND FIBRINOGEN IN CORONARY ARTERY DISEASE:

As diabetes and fibrinogen share most of the conventional risk factor\(^3^8\) such as obesity, smoking, dyslipidemia, etc. contribution of diabetes and hyperfibrinogenemia\(^4^5\) together causes significantly increased risk of atherosclerotic coronary artery disease.

Role of fibrinogen in Atherosclerosis and Thrombosis has been postulated due to \(^4^6\) factors given below

- Magnified aggregation of platelet.
– Escalated Fibrin synthesis.

– Increased vascular smooth muscle cell proliferation.

So Hyperfibrinogenemia causes Atherothrombosis of varying degree depending upon its level.

FIBRINOGEN

Fibrinogen is a key component in coagulation process. It is a glycoprotein synthesized in liver by liver cells. It is about 340 kDa. Its normal serum level is 1.5 – 4.0 g/L.

It has an important role in final path of coagulation cascade where thrombin converts fibrinogen to fibrin. This fibrin is cross linked by factor VIII to form a clot. Thrombin and t-PA activates factor VIII and this is catalyzed by fibrin\textsuperscript{47}.

Factor Xa and thrombin, which is involved in fibrinolysis, are transiently inhibited by fibrin, which engulf them within the fibers. There they remain viable to be released during fibrinolysis\textsuperscript{48}. 

36
COAGULATION CASCADE:

Fibrinogen deficiency

- It can be congenital or acquired. Congenital deficiency is rare and been reported in few.
**Dysfibrinogenemia**

Gene controlling synthesis of Fibrinogen in liver undergoes mutation and causes Dysfibrinogenemia, a rare coagulopathic condition.

It causes failure of degradation of fibrinogen, while being converted to fibrin. These patients are prone for venous thrombosis and bleeding in rare instance.

Genetic molecular testing is used to detect the culprit genetic mutation, responsible for

- Inherited Dysfibrinogenemia
- Hypofibinogenemia (or)
- Afibrinogenemia

**Causes of Acquired deficiency**

- Sepsis
- Severe trauma with extensive tissue loss
- Disseminated intravascular coagulation
- Massive blood loss
- Post Hemodilution.
- Drugs
- Anabolic steroids
- Phenobarbitol
- Streptokinase
- Valproic acid

**Estimation of Fibrinogen**

It can be ascertained using venous blood. Normally it ranges from 1.5 – 4 g/L depending upon the laboratory method adopted. It can be estimated with blood serum or plasma.

In plasma, it is measured by CLAUSs method which shows an inverse relationship between clotting time and plasma Fibrinogen level.

Fibrinogen level increases with BMI, smoking, fasting insulin levels, LDL, WBC Count, Diabetes and Pregnancy. Whereas it is reduced in moderate alcohol usage, exercise, high level of high density lipoprotein and hormone replacement therapy. 49,50,51
Fibrinogen poses significant risk for cardiovascular disorders.\textsuperscript{52,53} It’s positive relationship with BMI has been established by a study which showed decrease in fibrinogen level following low calorie healthy diet for 6 months\textsuperscript{54} and this may be the mechanism by which obesity increases the risk of cardiovascular disease. Also fibrinogen level are high in diabetes\textsuperscript{55} than controls.

Obesity can be a link between diabetes and fibrinogen in causing adverse cardiac event mediated by fibrinogen and other traditional cardiovascular risk factor such as BMI, obesity, etc.

Poor glycemic status are often associated with increased fibrinogen level\textsuperscript{56} and this is evidenced by the observation of increased platelet reactivity in Diabetics and this may be due to high fibrinogen level which cross bridges platelets.

Fibrinogen as a predictor of adverse coronary events in angina patients has been established by a study conducted by Thompson &colleagues\textsuperscript{57}. This further
establishes T2DM as a high risk event for cardiovascular disease.\textsuperscript{58,59}

Increased risk for cardiovascular disease in smokers can be attributable to high level of fibrinogen found in smokers than in non-smokers. This association has been established by study conducted by Fogari et al\textsuperscript{60} which showed a linear relationship between fibrinogen level and number of cigars smoked.

It is well established that Diabetes have increased risk of adverse cardiac events. Plaque rupture and thrombosis are the key components in acute coronary syndrome. Pathogenesis of these events are largely contributed by inflammatory pathology as evidenced by increased level of fibrinogen and C-reactive protein in patients with unstable angina\textsuperscript{61}.

A study by Emansh et al, suggest a strong link between high plasma fibrinogen level and Premature CAD\textsuperscript{62}.Role of Fibrinogen in the causation of
Atheroembolic events is further accomplished by several studies showing strong link between Fibrinogen level and

- Ischemic Cerebrovascular accident$^{63,64,65}$
- Peripheral vascular disease$^{66,67}$

Fibrinogen, an acute phase reactant and a procoagulant in addition, is being centered around the pathophysiology of atherosclerosis. Hence it is being considered as a significant factor in the pathogenesis of coronary artery disease, especially in T2DM patients where its serum level is higher than non diabetic population.

Recently the role of fibrinogen level in serum in predicting subsequent major adverse cardiac events in known Diabetics with coronary artery disease patients is being studied extensively.
MATERIALS AND METHODS

Study site

Department of General Medicine, Government Stanley Medical college and Hospital, Chennai.

Collaborating Departments

- Department of Cardiology
- Department of Medical Biochemistry

Study Design

- Cross sectional study

Study Period

- June 2012 to November 2012

Selection of study population

- Inclusion criteria

Diabetic inpatients with past history or evidence of Coronary artery disease.
Exclusion Criteria

- Disseminated intravascular coagulation
- Pregnancy
- Liver disease
- Sepsis
- Drug abuse like OCP, Antifibrinolytic, hormones
- Dysfibrinogenemia

Investigations done

- Complete blood count
- Blood sugar – Random, fasting and post prandial
- Glycosylated Hb
- Blood urea
- Serum creatinine
- Urine routine analysis
- ECG
- ECHO
- Serum fibrinogen
Sample size

- Using the above mentioned criteria 50 subjects were recruited

Sampling method

- Convenience sampling method was adopted

Study protocol

- Subjects recruited as per inclusion and exclusion criteria
- Results of investigation noted
- Serum fibrinogen estimated
- Adverse cardiac events noted
- Data entry in MS Excel 2010
Estimation of Serum fibrinogen

Clauss method

The determination of fibrinogen with thrombin clotting time is based on the method originally described by Clauss; in the presence of an excess of thrombin, fibrinogen is transformed into fibrin and clot formation time is inversely proportional to the concentration of fibrinogen in the sample plasma.

Reagents

Fibrinogen reference

- Lyophilized human plasma containing buffer and preservative

Thrombin reagent

- Lyophilized preparation containing bovine thrombin, approximately 75 NIH U/ml, buffer, stabilizers and preservative

Imidazole buffer

- Imidazole 30 mmol/L
- Sodium chloride 125 mmol/L
- Sodium azide 0.1% as preservative, pH 7.35
Sample

- Venous blood collected in 3.8% sodium citrate in a ratio of 9 parts of blood to 1 part of anticoagulant (1:10)

Procedure

- Reconstitution of Thrombin agent done and maintained at room temperature (18-26°C) during testing
- To the fibrometer cup 0.2ml of the diluted plasma sample added
- To the fibrometer cup 0.2ml of the diluted plasma sample added
- This is incubated for 1-3 minutes at 37°C for not more than 5 minutes
- After incubation 0.1 ml of Thrombin reagent is added rapidly into the fibrometer while simultaneously starting the timer
- Clotting time results recorded in seconds
- Extrapolation of concentration done from calibration curve
- Results evaluated and tabulated
Major adverse cardiac events

- Recurrent angina (RA)
- Congestive cardiac failure (CCF)
- Arrhythmia (AR)
- Death (CD)
RESULTS

This study was done to correlate the plasma fibrinogen levels in major adverse cardiac events occurring in known diabetic coronary artery disease patients who were admitted as in patients in Department of Medicine, Government Stanley Medical College, Chennai.

Age distribution

Chart 1

The total number of study subjects is N=50. Among them the age distribution ranges from 44 to 78 years. The majority of the patients belonged to the 44-78 years age group (42%) (Chart 1)
As far as the gender distribution is concerned 66% of the study subjects are males and 34% of them are females. (Chart 2)
**Group wise distribution of study population demographic characteristics**

**Table 1**

|                      | No MACE (n=24) | Recurrent Angina (n=11) | Congestive Cardiac Failure (n=15) | Arrhythmia (n=0) | Death (n=0) |
|----------------------|----------------|-------------------------|----------------------------------|------------------|-------------|
| Age                  | 57.33          | 63.92                   | 65.2                             | 0.00             | 0.00        |
| Duration of Diabetes | 11.4           | 13.54                   | 15.55                            | 0.00             | 0.00        |
| Fasting Blood Sugar  | 139.78         | 187.85                  | 213.68                           | 0.00             | 0.00        |
| Post Prandial Blood Sugar | 250.87 | 299.54                   | 332.18                           | 0.00             | 0.00        |
| HBA$_{1C}$           | 9.22           | 9.98                    | 10.03                            | 0.00             | 0.00        |
| Serum Fibrinogen     | 306.07         | 344.08                  | 426.32                           | 0.00             | 0.00        |

Table 1 displays the demographic data with mean values of age of patients, duration of diabetes, fasting blood sugar, post prandial blood sugar, glycosylated haemoglobin (HBA$_{1C}$) and serum fibrinogen levels.
The mean values have been matched against the major adverse cardiac events (MACE) groups – recurrent angina, congestive cardiac failure, arrhythmia and death. Patients who do not develop MACE are captured in a separate group.

**Prevalence of Major Adverse Cardiac Events**

**Table 2**

| MACE                        | No of Patients | Percentage (%) |
|-----------------------------|----------------|----------------|
| No MACE                     | 24             | 48             |
| Recurrent Angina            | 11             | 22             |
| Congestive cardiac failure  | 15             | 30             |
| TOTAL                       | 50             | 100            |

The observations made by Table 2 suggests that, the highest prevalence is that of patients who do not develop MACE(48%). This group is followed by the congestive cardiac failure group (30%). Arrhythmia and death groups will no longer be considered in this study due to no responses.
Relationship between MACE and patient age

Table 3A

| Age            | 40-49 | 50-59 | 60-69 | 70-79 | TOTAL |
|----------------|-------|-------|-------|-------|-------|
| No MACE        | 5     | 11    | 9     | 1     | 26    |
| Recurrent Angina | 1     | 1     | 3     | 2     | 7     |
| Congestive cardiac failure | 0     | 2     | 9     | 6     | 17    |
| TOTAL          | 6     | 14    | 21    | 9     | 50    |

$X^2 = 17.97$  $P=0.0063$

From Table 3A the following observations can be made:

- 26 patients did not suffer from MACE
- 7 had recurrent angina and 17 had congestive cardiac failure
- In the group which did not have MACE more numbers clustered around the age groups of 50-59 and 60-69
- RA group has more numbers clustered around 60-69 age group
- Similarly the CCF group is clustered around 60-69 age group
Statistical Comparisons

Table 3B

| Comparisons                              | ‘t’ | ‘p’    |
|------------------------------------------|-----|--------|
| No MACE - Recurrent Angina              | 2.77| <0.001 |
| Recurrent Angina - Congestive cardiac failure | 0.83| >0.05  |
| Congestive cardiac failure - No MACE    | 4.44| <0.001 |

From Table 1 it can be seen that the mean ages of study groups No MACE, AR and CCF are 57, 64 and 66 respectively.

The above mentioned mean age groups were compared with each other as shown in table 3B using Student’s unpaired t test.

On comparison of the No MACE and RA group a p value of <0.001 was arrived at and similarly comparing the age groups of RA and CCF yield a p value of <0.001 both highly significant.
Relationship between MACE and sex of the patient

Table 4

|                          | Male     | Female   | TOTAL |
|--------------------------|----------|----------|-------|
| No MACE                  | 20(40%)  | 8(16%)   | 28    |
| Recurrent Angina         | 4(8%)    | 4(8%)    | 8     |
| Congestive cardiac failure| 9(18%)   | 5(10%)   | 14    |
| TOTAL                    | 33(66%)  | 17(44%)  | 50    |

$X^2 = 2.37$  
$P = 0.305$

Table 4 revealed the following details:

- In the No MACE group there were 20 men and 8 women
- The RA group consisted of 4 men and 4 women
- CCF group had 9 men and 5 women
- In total there were 33 men and 17 women
- The numbers when analysed statistically, yielded a chi square value of 2.37 and a p value of 0.305 (not significant)
Relationship between MACE and duration of Diabetes

Table 5

|                  | 5-10y | 11-15y | >15y | TOTAL |
|------------------|-------|--------|------|-------|
| No MACE          | 6     | 19     | 4    | 29    |
| Recurrent Angina | 1     | 2      | 5    | 8     |
| Congestive cardiac failure | 1    | 3      | 9    | 13    |
| TOTAL            | 8     | 24     | 18   | 50    |

$X^2 = 14.87$  $P=0.005$

From Table 5 the following can be gathered:

- No MACE group consists of 29 patients and clustering is seen in the 5-10 and 11-15 years duration group.
- In contrast RA group showed only 1 patient who developed recurrent angina within 10 years of diabetes and majority developed it after 15 years of diabetes.
- CCF group showed the same picture as RA group.
- Chi square test was used to analyse and revealed a p value of 0.005 (statistically significant).
### Relationship between MACE and Fasting blood sugar

**Table 6**

| FBS (mg/dl) | 90-140 | 141-190 | 191-240 | 241-290 | TOTAL |
|-------------|--------|---------|---------|---------|-------|
| No MACE     | 15     | 11      | 0       | 0       | 26    |
| Recurrent Angina | 0     | 3       | 4       | 0       | 7     |
| Congestive cardiac failure | 0     | 1       | 9       | 7       | 17    |
| TOTAL       | 15     | 15      | 13      | 7       | 50    |

$X^2 = 56.30 \quad P = <0.0001$

From the above table, it can be seen that:

- Majority of the patients in the No MACE group belonged to the FBS 90-140 range
- In the RA group, highest number of patients belonged to FBS 191-240 range
- In the CCF most of the clustering was around 191-240 and 241-290 range
- However the last FBS group, 241-290 range had only 7 patients
Relationship between MACE and Post Prandial blood sugar

Table 7

| PPBS        | 190-240 | 241-290 | 291-340 | 341-390 | TOTAL |
|-------------|---------|---------|---------|---------|-------|
| No MACE     | 12      | 8       | 5       | 0       | 25    |
| Recurrent   | 0       | 2       | 4       | 0       | 6     |
| Angina      |         |         |         |         |       |
| Congestive  | 0       | 1       | 7       | 7       | 15    |
| cardiac     |         |         |         |         |       |
| failure     |         |         |         |         |       |
| TOTAL       | 12      | 11      | 16      | 7       | 50    |

$X^2 = 55.69 \quad P = <0.0001$

It can be seen from this table:

- Among the No MACE group, large number of patients belong to the 190-240 and 241-290 PPBS range. 341-390 range did not have any patients.
- RA group shows 4 patients in 291-390 range and nil patients in 190-240 and 341-390 ranges
- CCF group shows equal presence of patients in 291-340 and 341-390 range
Relationship between MACE and Glycemic control

Table 8

|                  | Well controlled | Uncontrolled | TOTAL |
|------------------|-----------------|--------------|-------|
|                  | HBA$_{1C}$ 6.2-8.3 | HBA$_{1C}$>8.3 |
| No MACE          | 20              | 8            | 28    |
| Recurrent Angina | 1               | 7            | 8     |
| Congestive cardiac failure | 0      | 14           | 14    |
| TOTAL            | 9               | 41           | 50    |

$X^2 = 8.21$  \hspace{1cm} P = <0.0165

From this table it can be clearly seen that more patients under the No MACE group are under the well-controlled HBA$_{1C}$ group (20 out of 28). But in the RA and CCF groups very few patients are under the well-controlled HBA$_{1C}$ group (1 and 0 respectively). The category of poorly maintained HBA$_{1C}$ group has the largest number of patients (41 out of 50). Chi square test was used to analyse and revealed a p value of 0.0165 (statistically significant)
Relationship between Serum Fibrinogen levels & patient age

Table 9

| Serum Fibrinogen (mg/dl) | Age of the patient (years) |
|--------------------------|---------------------------|
|                          | 40-49 | 50-59 | 60-69 | 70-79 |
| 200-250                  | 1     | 0     | 1     | 0     |
| 251-300                  | 1     | 4     | 1     | 1     |
| 301-350                  | 3     | 7     | 3     | 1     |
| 351-400                  | 0     | 1     | 1     | 0     |
| >400                     | 1     | 3     | 15    | 6     |
|                          | 6     | 15    | 21    | 8     |

$X^2 = 3.47 \quad P = >0.05$

The serum fibrinogen levels were recorded in 50 patients with major adverse cardiac events. It can be seen that serum fibrinogen levels 200-250 range has only 1 patient in 40-49 and 60-69 age groups with other groups recording nil entries. In the serum fibrinogen levels 251-300 category, majority of the patients are seen in the 50-59 age groups. Similar picture is reflected in serum fibrinogen levels category 301-350. There are nil patients in the age groups 50-59 and 60-69 under serum fibrinogen levels category 351-400. In contrast serum fibrinogen levels category >400 shows the highest number of patients in the 60-69 age group.
Relationship between Serum Fibrinogen levels and sex of the patient

Table 10

|                        | Mean serum fibrinogen (mg/dl) | Male    | Female   | P value |
|------------------------|------------------------------|---------|----------|---------|
| No MACE                |                              | 299.71  | 311.29   | 0.29    |
| Recurrent Angina       |                              | 349.33  | 339.57   | 0.64    |
| Congestive cardiac failure |                        | 431.39  | 419.00   | 0.41    |

It can be seen from the above table that, among the No MACE group, the women had a mean serum fibrinogen level of 311, while the men had a mean serum fibrinogen level of nearly 300. In the RA group, the women had a mean serum fibrinogen level of 339, while the men had a mean serum fibrinogen level of 349. Finally in the CCF group, the women had a mean serum fibrinogen level of 419, while the men had a mean serum fibrinogen level of 431. The three groups had p values of 0.29, 0.64 and 0.41, all of them not statistically significant.
Relationship between Serum Fibrinogen levels and duration of Diabetes

Table 11

| Mean serum fibrinogen (mg/dl) | No of cases according to duration of disease |
|-------------------------------|---------------------------------------------|
|                               | 5-10 | 11-15 | >15  |
| No MACE                       | 6    | 19    | 4    |
| Recurrent Angina              | 1    | 2     | 5    |
| Congestive cardiac failure    | 1    | 3     | 9    |
| Mean serum fibrinogen         | 319  | 337   | 375  |

\[ X^2 = 14.87 \quad P = 0.01 \]

Table 11 reveals the following

- Patients with diabetes for 5-10 years have a mean serum fibrinogen level of 319 mg/dl with maximum patients having no MACE
- Patients with diabetes for 11-15 years have a mean serum fibrinogen level of 337 mg/dl with maximum patients having no MACE
- Patients with diabetes for more than 15 years have a mean serum fibrinogen level of 375 mg/dl with maximum patients in the CCF group
• Statistical comparisons yielded a chi square value of 14.87 and p value of <0.01 (statistically significant)

**Relationship between Serum Fibrinogen levels and Fasting blood sugar**

**Table 12A**

| FBS          | 90-140 | 141-190 | 191-240 | 241-290 |
|--------------|--------|---------|---------|---------|
| Mean serum fibrinogen | 298.71 | 333.31  | 406.62  | 424     |
| No of Cases  | 15     | 21      | 12      | 2       |

**Statistical comparisons**

**Table 12B**

| Comparisons          | Z value | P value |
|----------------------|---------|---------|
| (90-140) – (141-190) | 3.46    | <0.01  |
| (141-190) - (191-240)| 5.22    | <0.001 |
| (191-240) - (241-290)| 1.3     | >0.05  |
From the above table, it can be seen that:

- 15 patients belonged to the FBS 90-140 range with mean serum fibrinogen level of 299 mg/dl nearly
- 21 patients belonged to the FBS 141-190 range with mean serum fibrinogen level of 333 mg/dl
- 12 patients belonged to the FBS 191-240 range with mean serum fibrinogen level of 406 mg/dl
- 2 patients belonged to the FBS 241-290 range with mean serum fibrinogen level of 424 mg/dl
- Statistical comparisons were performed between categories (90-140) – (141-190), (141-190) - (191-240) and (191-240) - (241-290). The z value obtained was 3.46, 5.22 and 1.3 respectively. The corresponding p values were <0.01, <0.001 (both statistically significant) and >0.05
Relationship between Serum Fibrinogen levels and Post Prandial blood sugar

Table 13A

| PPBS    | 190-240 | 241-290 | 291-340 | 341-390 |
|---------|---------|---------|---------|---------|
| Mean    | 295.77  | 332.1   | 365.18  | 425.1   |
| serum   |         |         |         |         |
| fibrinogen |       |         |         |         |
| No of   | 13      | 12      | 18      | 7       |
| Cases   |         |         |         |         |

Statistical comparisons

Table 13B

| Comparisons | Z value | P value |
|-------------|---------|---------|
| (190-240)   | – 2.9   | <0.01   |
| (241-290)   |         |         |
| (241-290)   | - 2.15  | <0.05   |
| (291-340)   |         |         |
| (291-340)   | - 3.81  | <0.001  |
| (341-390)   |         |         |
From the above table, it can be seen that:

- 13 patients belonged to the PPBS 190-240 range with mean serum fibrinogen level of 295.77 mg/dl
- 12 patients belonged to the PPBS 241-290 range with mean serum fibrinogen level of 332 mg/dl
- 18 patients belonged to the PPBS 291-340 range with mean serum fibrinogen level of 365 mg/dl
- 7 patients belonged to the PPBS 341-390 range with mean serum fibrinogen level of 425 mg/dl
- Statistical comparisons were performed between categories (190-240) – (241-290), (241-290) - (291-340) and (291-340) - (341-390). The z value obtained was 2.9, 2.15 and 3.81 respectively. The corresponding p values were <0.01, <0.05 and <0.001 (all statistically significant)
Relationship between Serum Fibrinogen and Glycemic control

Table 14

|                  | Well controlled | Uncontrolled | TOTAL |
|------------------|-----------------|--------------|-------|
|                  | HBA$_{1C}$ 6.2-8.3 | HBA$_{1C}>8.3$ |       |
| Mean fibrinogen values | 315.06 | 354.10 | 28    |
| No of Cases      | 11              | 39           | 8     |
| Z value          | 2.67            |              |       |
| P value          | <0.01           |              |       |

In this table, it is seen that mean serum fibrinogen value for the category of well controlled (11 patients) HBA$_{1C}$ was 315.06, while the mean serum plasma fibrinogen value for the category of poorly controlled (39 patients) HBA$_{1C}$ was 354.10. Statistical comparisons of mean serum fibrinogen values of the two categories yielded a z value of 2.67 and a p value of <0.001 (statistically significant).
Relationship between Serum Fibrinogen levels and MACE

Table 15A

| MACE                        | No of Patients | Mean serum fibrinogen levels |
|-----------------------------|----------------|-----------------------------|
| No MACE                     | 24             | 306.07                      |
| Recurrent Angina            | 11             | 344.08                      |
| Congestive cardiac failure  | 15             | 426.32                      |

Statistical comparisons

Table 15B

| Comparisons                  | ‘t’   | ‘p’     |
|------------------------------|-------|---------|
| No MACE - Recurrent Angina   | 3.89  | <0.001  |
| Recurrent Angina - Congestive cardiac failure | 6.63  | <0.001  |
| Congestive cardiac failure - No MACE | 14.84 | <0.001  |
Tables above reveal that

- No MACE category has 24 patients with mean serum fibrinogen level of 306.07 mg/dl
- RA category has 11 patients with mean serum fibrinogen level of 344.08 mg/dl
- CCF category has 15 patients with mean serum fibrinogen level of 426.32 mg/dl
- Comparisons between mean serum fibrinogen levels of No MACE - Recurrent Angina category yielded a t value of 3.89
- Comparisons between mean serum fibrinogen levels of Recurrent Angina - Congestive cardiac failure category yielded a t value of 6.63
- Comparisons between mean serum fibrinogen levels of Congestive cardiac failure - No MACE category yielded a t value of 14.84
- All of the comparisons had a p value of <0.001
DISCUSSION

The present study, which is cross sectional in design, has a sample size of 50 patients of Diabetes mellitus with coronary artery disease. Among the 26 patients with major adverse cardiac events 11 had recurrent angina (22%) and 15 had congestive cardiac failure(30%).

The relationship between patient age and major adverse cardiac events among 50 patients were obtained from table 3. They revealed that the severity of major adverse cardiac events increased with the increasing age of the patients in a statistically significant manner.

Although there is a higher number of males than females with regard to total number of patients, it is evident that there is no significant variation in major adverse cardiac events in relation to gender of the patient.
More patients with recurrent angina and congestive cardiac failure were among those patients with diabetic age more than 15 years (table 6). The findings prove that worsening of major adverse cardiac events with increasing duration of diabetes in these individuals is statistically significant.

Regarding the relationship of fasting blood sugar and post prandial blood sugar levels with the severity of major adverse cardiac events, it was observed that there is a statistically significant increase in the severity of major adverse cardiac events with increasing values of FBS and PPBS.

One of the studies conducted previously in this regard found that risk of major adverse cardiac events six times more among patients with poor glycemic control. 68
Serum fibrinogen is one of the important factors that leads to the increased viscosity of blood, especially in diabetics. It is known for its role in end organ diseases. In this study serum fibrinogen levels was compared with various parameters and statistically analysed. The observations and interpretations are as follows

- No correlation found between the age of the patients and gender of the patients with their levels of serum fibrinogen

- When serum fibrinogen levels were correlated with various parameters regarding the diabetic age, blood sugar and glycemic control, mean serum fibrinogen was found to be in correlation with all the above parameters. It means that with progression and increase in severity of diabetes, there is a noticeable rise in mean serum fibrinogen titres.
• This could be attributed to the reason that long standing and poorly controlled diabetes is associated with greater incidence of macro vascular pathologies. It is seen in a related study that serum fibrinogen levels were higher in those diabetics with poor metabolic control 69

• There is a positive correlation between major adverse cardiac events and mean serum fibrinogen levels. Increase in severity of major adverse cardiac events causes simultaneous increase in serum fibrinogen. Other similar studies have concluded stating that fibrinogen may be involved in increased cardiovascular risk of patients with diabetes 70,58
SUMMARY & CONCLUSION

The summary of results obtained is as follows:

- The study included 50 diabetic patients with coronary artery disease.
- Age varied from 44 to 78 years
- 52% of the patients suffered from major adverse cardiac events (recurrent angina and congestive cardiac failure)
- Older patients had more severe forms of major adverse cardiac events
- There is no significance between gender of patients and severity of major adverse cardiac events
- Longer the duration of diabetes more severe the major adverse cardiac events
- Higher blood sugar levels and poorer glycemic control leads to severe major adverse cardiac events
- No correlation between mean serum fibrinogen level and age or gender of the patient
• Mean serum fibrinogen levels was significantly higher in patients with longer duration of diabetes, higher blood sugars and poor glycemic control

• Increase in severity of major adverse cardiac events correlates with increase in serum fibrinogen titres
BIBLIOGRAPHY

1. Harrisons principle of medicine, 18th edition

2. W.B Kannel et at, Diabetes and cardiovascular disease. Diabetes care, vol 2, no, march – april

3. Epstein, F. H.: "Hyperglycemia"—a risk factor in coronary disease. Circulation 36: 609-619, 1967.

4. Gertler, M. M., Leetrria, H. E., Salute, E., et al.: Ischaemic heart disease. Insulin, carbohydrate and lipid interrelationships. Circulation 46: 103-111, 1972.

5. Heinle, R. A., Levy, R. I., Fredrickson, D. S., and Gorlin, R.: Lipid and carbohydrate abnormalities in patients with angiographically documented coronary artery disease. Am. J. Cardiol. 24: 178, 1969.

6. Stamler, J., Berkson, D. M., and Lindberg, H. A.: Risk factors: Their role in the etiology and pathogenesis of the atherosclerotic diseases. In The Pathogenesis of the Atherosclerotic Diseases. Wissler, R. W., and Geer, J. C, Eds. Baltimore, Williams & Wilkins 1972, pp. 67-69.
7. Kannel, W. B., Hjortland, M., and Castelli, W. P.: Role of diabetes in congestive heart failure: The Framingham Study. Am. J. Cardiol. 34: 29-34, 1974.

8. Davidsons Principles and Practice of Medicine, 21st edition, page 800.

9. Garcia, M., McNamara, P., Gordon, T., and Kannel, W. B.: Cardiovascular complications in diabetics. Adv. Metab. Disord. Suppl. 2: 493-499, 1973.

10. Pell, S., and d'Alonzo, C. A.: Some aspects of hypertension in diabetes mellitus, J.A.M.A. 202: 104-110, 1967.

11. Jarret, R. J., and Keen, H.: Diabetes and atherosclerosis. In Complications of Diabetes. Keen, H., and Jarret, R. J., Eds. London, Edward Arnold Co., 1975, pp. 179-203.

12. Kaufmann, R. L, Assal, J., Soeldner, J. S., Wilmhurst, E. G., Lemaira, J. R., Gleason, R. E., and White, P.: Plasma lipid levels in diabetic children. Effect of diet restricted in cholesterol and saturated fats. Diabetes 24: 672-679, 1975.
13. **Kissebah, A. H., Siddig, Y. K., Kohner, E. M., Lowy, C, Lewis, B., and Fraser, T. R.**: Plasma lipids and glucose insulin relationship in non-insulin-requiring diabetics with and without retinopathy. Lancet J: 1104-1107, 1975.

14. **Lowy, A. D. and Barach, J. H.**: Predictive value of lipoprotein and cholesterol determinations in diabetic patients who developed cardiovascular complications. Circulation 18: 14-21, 1958.

15. **Goodkin, G.**: Mortality factors in diabetes. J. Occup. Med. 17: 716-721, 1975.

16. University Group Diabetes Program: A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. Diabetes 19 (Suppl. 2): 747-830, 1970

17. **Ozcan, U, et al.** Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science. 2004. 306:457-461.

18. **Nakatani, Y, et al.** Involvement of endoplasmic reticulum stress in insulin resistance and diabetes. J. Biol. Chem. 2005. 280:847-851.
19. **Ozawa, K, et al.** The endoplasmic reticulum chaperone improves insulin resistance in type 2 diabetes. Diabetes. 2005. 54:657-663

20. **Lin, Y, et al.** The hyperglycemia-induced inflammatory response in adipocytes: the role of reactive oxygen species. J. Biol. Chem. 2005. 280:4617-4626.

21. **Furukawa, S, et al.** Increased oxidative stress in obesity and its impact on metabolic syndrome. J. Clin. Invest. 2004. 114:1752-1761.

22. **Hotamisligil, GS, et al.** IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science. 1996. 271:665-668.

23. **Aguirre, V, et al.** The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J. Biol. Chem. 2000. 275:9047-9054.

24. **Aguirre, V, et al.** Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action. J. Biol. Chem. 2002. 277:1531-1537.
25. **Paz, K, et al.** A molecular basis for insulin resistance. Elevated serine/threonine phosphorylation of IRS-1 and IRS-2 inhibits their binding to the juxtamembrane region of the insulin receptor and impairs their ability to undergo insulin-induced tyrosine phosphorylation. J. Biol. Chem. 1997. 272:29911-29918.

26. **Xu, H, et al.** Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. 2003. 112:1821-1830. doi:10.1172/JCI200319451.

27. **M. Centofani,** "Diabetes Complications: More than Sugar?" Science News, vol. 149, no. 26/27, Dec. 23–30, p. 421 (1995)

28. **Rich SS (February 2006).** "Genetics of diabetes and its complications". J. Am. Soc. Nephrol. 17 (2): 353–60.

29. **Fong DS, Aiello LP, Ferris FL 3rd, Klein R:** Diabetic retinopathy. Diabetes Care 27:2540 -2553,

30. **Keenan HA, Costacou T, Sun JK, Doria A, Cavellerano J, Coney J, Orchard TJ, Aiello LP, King GL:** Clinical factors associated with resistance to microvascular complications in diabetic patients of
extreme disease duration: the 50-year medalist study. Diabetes Care 30: 1995-1997, 2007

31. Aiello LP, Pierce EA, Foley ED, Takagi H, Chen H, Riddle L, Ferrara N, King GL, Smith LE: Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A 92: 10457-10461, 1995

32. Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T: Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 28: 164-176, 2005

33. Heart Outcomes Prevention Evaluation Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355: 253-259, 2000

34. Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, Malik RA, Maser RE, Sosenko JM, Ziegler D: Diabetic neuropathies: a statement by the
American Diabetes Association. Diabetes Care 28:956-962, 2005

35. **Pankaj et al., INT. J. DIAB. DEV. COUNTRIES (2004). VOL.24**

36. **Beckman JA, Creager MA, Libby P:** Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA287: 2570-2581, 2002

37. **Moreno PR, Murcia AM,** composition and macrophage infiltration in atherectomy specimens Palacios IF, et al. coronary from patients with diabetes mellitus. Circulation 2000; 102: 2180-4

38. **d Underwood and Cross, James, (2009).** General ans Systematic Pathology. London: Churchilllivingstone. pp. 279.

39. **Smith FB, Lee AJ, Fowkes FG, Price JF, Rumley A, Lowe GD (November 1997).** "Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study". ArteriosclerThrombVasc Biol. 17 (11): 3321–5.

40. **Danesh J, Collins R, Peto R (2000).** "Lipoprotein(a) and coronary heart disease. Meta analysis of prospective studies". Circulation 102 (10): 1082–5.
41. Ghatrehsamani K, Darabi M, Rahbani M, Hashemzadeh Chaleshtory M, Farrokhi E, Noori Mki (2009). "Combined hepatic lipase -514C/T and cholesteryl ester transfer protein I405V polymorphisms are associated with the risk of coronary artery disease". Genet Test Mol Biomarkers 13 (6): 809–15.

42. "5. Population nutrient intake goals for preventing diet-related chronic diseases". WHO

43. Swardfager W, Herrmann N, Cornish S, Mazereeuw G, Marzolini S, Sham L, Lanctôt KL (2012). "Exercise intervention and inflammatory markers in coronary artery disease: a meta-analysis". Am Heart J 163 (4): 666-676.

44. Jing M, Charles H, Hennekens PM, Stampfer MJ. A prospective study of fibrinogen and risk of myocardial infarction in the physician Health Study. J AmerCollCardiol 1999; 33: 1347-52.

45. James JS, Silbershatz H, Geoffrey H et al. Association of Fibrinogen with Cardiovascular Risk Factors and Cardiovascular Disease in the
Framingham Offspring Population. Circulation 2000; 102:1634-8.

46. **Liu Y, Saha N, Heng CK.** Fibrinogen genotypes (and) are associated with plasma fibrinogen levels in Chinese Journal of Medical Genetics 2001;38:e31

47. **Muszbek L, Bagoly Z, Bereczky Z, Katona E (July 2008).** "The involvement of blood coagulation factor XIII in fibrinolysis and thrombosis". Cardiovascular & Hematological Agents in Medicinal Chemistry 6 (3)190–205.

48. **Kaiser B (2003).** "DX-9065a, a direct inhibitor of factor Xa". Cardiovascular Drug Reviews 21 (2): 91–104.

49. **Neil A, Hawkins M, Potok M, Thorogood M, Cohen D and Mann J.** A prospective population-based study of microalbuminuria as a predictor of mortality in NIDDM. Diabetes Care 1993; 16: 996-1003.

50. **Folsom AR, Wu KK, Davis CE, Conlan M G, Sorlie P D, Szklo M.** Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors. Atherosclerosis 1991; 91: 191-205.
51. **Dotevall A, Johansson S, Wilhelmsen L.** Association between fibrinogen and other risk factors for cardiovascular disease in men and women. Results from the Goteborg MONICA survey 1985. Ann Epidemiol 1994; 4: 369–74.

52. **Meade TW, Brozovic M, Chakrabarti RR, et al.** Hemostatic function and ischemic heart disease: principal results of the Northwick Park Heart Study. Lancet. 1986;6:533–537.

53. **Kannel WB, Wolf PA, Castelli WP, et al.** Fibrinogen and risk for cardiovascular disease. JAMA. 1987;258:1183–1186.

54. **Ditschuneit HH, Flechtner-Mors M, Adler G.** Fibrinogen in obesity before and after weight reduction. Obesity Res. 1995;3:43–48.

55. **Ganda OP, Arkin CF.** Hyperfibrinogenemia, an important risk factor for vascular complications in diabetes. Diabetes Care 1992; 15: 1245-50.

56. **Vanninen E, Laitinen J, Uusitupa M.** Physical activity and fibrinogen concentration in newly diagnosed NIDDM. Diabetes Care. 1994;17: 1031–1038.
57. **Thompson SG, Keinast J, Pyke SDM, et al.** Hemostatic factors and their risk of myocardial infarction or sudden death in patients with angina pectoris (ECAT). N Engl J Med. 1995;332:635–641.

58. **Kannel WB, D’Agostino RB, Wilson P W, Belanger A J, Gagnon D R.** Diabetes, fibrinogen and risk of cardiovascular disease: the Framingham experience. Amer Heart J 1990; 120: 6726.

59. **Lee AJ, Lowe GD, Woodward M, Tunstall-Pedoe H.** Fibrinogen in relation to personal history of prevalent hypertension, diabetes, stroke, intermittent claudication, coronary heart disease, and family history: the Scottish Heart Health Study. Brit Heart J 1993; 69: 338-42.

60. **Fogari R, Zoppi A, Marasi G, et al.** Association between plasma fibrinogen levels and cardiovascular risk factors in hypertensive men. J Cardiovasc Risk. 1994;1:341–60

61. **Berk BC, Weintraub WS, Alexander RW.** Elevation of C-reactive protein in “active” coronary artery disease. Am J Cardiol. 1990;65:168 –172.
62. Fac Med Baghdad 2010; Vol. 52, No.4 Received Feb.2010 Accepted Apr. 2010

63. Fey GH, Fuller GM. Regulation of acute phase gene expression by inflammatory mediators. MolBiol Med.1987;4:323-338.

64. Tanne D, Benderly M, Goldbourt U. et al. A prospective study of plasma fibrinogen levels and the risk of stroke among participants in the bezafibrate infarction prevention study. Am J Med.2001;111: 457-463.

65. Folsom AR, Rosamond WD, Shahar E. et al. Prospective study of markers of hemostatic function with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Circulation.1999;100:73

66. Fowkes FG. Fibrinogen and peripheral arterial disease. Eur Heart J.1995;16(suppl A):36-40.

67. Lee AJ, Fowkes FG, Lowe GD, Connor JM, Rumley A. Fibrinogen, factor VII and PAI-1 genotypes and the risk of coronary and peripheral atherosclerosis: Edinburgh Artery Study. Thromb Haemost.1999;81:553-560.
68. Jain A, Gupta HL, Narayan S: Hyperfibrinogenemia in patients of diabetes mellitus in relation to glycemic control and urinary albumin excretion rate. J Assoc Physicians India 2001; 49: 227-30.

69. RM Missov, RP Stolk, JG van der Bom, A Hofman, ML Bots, HA Pols and DE Grobbee. Plasma fibrinogen in NIDDM: the Rotterdam study Diabetes care, 1996: 19(2): 157-159

70. G Imperatore, G Riccardi, C Iovine, AA Rivellese and O Vaccaro Plasma fibrinogen: a new factor of metabolic syndrome, a population based study Diabetes care, 21(4): 157-159
PROFORMA

S.NO : 

DATE:

AGE:

IP NO:

NAME:

SEX:

UNIT:

PHONE NO.:

ADDRESS:

OCCUPATION:

EDUCATION

INCOME
INVESTIGATIONS:

CBC:
HB:
PCV:
TC:
DC:
ESR
BLOOD SUGAR- RBS
FBS
PPBS

Hb A1C:
FIBRINOGEN:
UREA:
CREATININE:
LIPID PROFILE:
URINE ROUTINE:

ECG:
ECHO:
டை விழா போட்டு 

நம்பிக்கை நடவடி கொள்ளியுள்ளனைத் தெரிவுக்கே 
நீங்க தெரியும் கலந்துகொள்ள முடியாது 
நீங்க பல்வேறு குழுவின் அடிப்படையில் அமையும்.
INSTITUTIONAL ETHICAL COMMITTEE,
STANLEY MEDICAL COLLEGE, CHENNAI-1

Title of the Work : A Study on serum fibrinogen as an independent predictor of Major Adverse cardiac events (MACE) in known diabetic coronary Artery Disease patients

Principal Investigator : Dr.M.Amudhan

Designation : PG in M.D (GM)

Department : Department of General Medicine
Government Stanley Medical College,
Chennai-1

The request for an approval from the Institutional Ethical Committee (IEC) was considered on the IEC meeting held on 11.06.2012 at the Council Hall, Stanley Medical College, Chennai-1 at 2PM

The members of the Committee, the secretary and the Chairman are pleased to approve the proposed work mentioned above, submitted by the principal investigator.

The Principal investigator and their team are directed to adhere to the guidelines given below:

1. You should inform the IEC in case of changes in study procedure, site investigator investigation or guide or any other changes.
2. You should not deviate from the area of the work for which you applied for ethical clearance.
3. You should inform the IEC immediately, in case of any adverse events or serious adverse reaction.
4. You should abide to the rules and regulation of the institution(s).
5. You should complete the work within the specified period and if any extension of time is required, you should apply for permission again and do the work.
6. You should submit the summary of the work to the ethical committee on completion of the work.

\[Signature\]

MEMBER SECRETARY,
IEC, SMC, CHENNAI
MASTER KEY

SBP : SYSTOLIC BLOOD PRESSURE
DBP : DIASTOLIC BLOOD PRESSURE
FBS : FASTING BLOOD SUGAR
PPBS : POSTPRANDIAL BLOOD SUGAR
ECG : ELECTROCARDIOGRAM
ECHO: ECHOCARDIOGRAM
TC : TOTAL CHOLESTROL
LDL : LOW DENSITY LIPOPROTEIN
HDL : HIGH DENSITY LIPOPROTEIN
VLDL: VERY LOW DENSITY LIPOPROTEIN
TGL : TRIGLYCERIDES
MACE: MAJOR ADVERSE CARDIAC EVENT
IWMI : INFERIOR WALL MYOCARDIAL INFARCTION
PRWP : POOR R WAVE PROGRESSION
EF : EJECTION FRACTION
T2DM : TYPE 2 DIABETES MELLITUS
SHT : SYSTEMIC HYPERTENSION
CAD : CORONARY ARTERY DISEASE
DCMP : DILATED CARDIOMYOPATHY
IDCMP : ISCHEMIC DILATED CARDIOMYOPATHY
CCF : CONGESTIVE CARDIAC FAILURE
RWMA : REGIONAL WALL MOTION ABNORMALITY
LVSE : LEFT VENTRICULAR SYSTOLIC FUNCTION
UA : UNSTABLE ANGINA
NSR : NORMAL SINUS RHYTHM
WNL : WITHIN NORMAL LIMIT
LVH : LEFT VENTRICULAR HYPERTROPHY
CKD : CHRONIC KIDNEY DISEASE
LVF : LEFT VENTRICULAR FAILURE
CVA : CEREBRO VASCULAR ACCIDENT
COPD : CHRONIC OBSTRUCTIVE PULMONARY DISEASE
PT : PULMONARY TUBERCULOSIS
ADD : ACUTE DIARRHOEAL DISEASE
LL : LOWER LOBE
DD : DIASTOLIC DYSFUNCTION
GERD : GASTRO ESOPHAGEAL REFLUX DISEASE
RA : RECURRENT ANGINA
AR : ARRRYTHMIAS
CD : DEATH
OCP : ORAL CONTRACEPTIVE PILLS
COPD : CHRONIC OBSTRUCTIVE LUNG DISEASE
| S.No. | Name          | Age | Sex | Duration of Diabetes in Years | FBS | PFS | PPBS | PPL | Diastolic BP | ECG           | Echo         | TC | LDL | HDL | VLDL | TOL | Urine | Creatinine | S. Fibrinogen | Diagnosis                                                                 |
|-------|---------------|-----|-----|-------------------------------|-----|-----|------|-----|--------------|---------------|-------------|----|-----|-----|-------|-----|-------|------------|--------------|--------------------------------------------------------------------------|
| 1     | Sivasamy      | 56  |     |                               | 5   | 178 | 233  | 182 | 292          | 6.1           | Non-hypotensive ml 190, EF 30% | 151 | 87 | 40 | 159 | 21 | 7   | 0.7        | 462          | T2DM/SHT/CAD/DM/PF/CCF                                                   |
| 2     | Sivasamy      | 56  |     |                               | 5   | 175 | 230  | 219 | 329          | 9.6           | No R/RMA, Normal LVSF | 150 | 90 | 30 | 16 | 81 | 32 | 1.2        | 177.8        | SHT/T2DM/COPD/CAD                                                     |
| 3     | Sivasamy      | 56  |     |                               | 5   | 175 | 144  | 108 | 218          | 8.9           | Normal LVSF | 151 | 87 | 28 | 16 | 81 | 17 | 0.8        | 105.2        | T2DM/SHT/CAU                                                   |
| 4     | Sivasamy      | 56  |     |                               | 5   | 175 | 162  | 122 | 272          | 8.4           | No R/RMA, Normal LVSF | 150 | 90 | 30 | 22 | 77 | 55 | 0.9        | 380          | T2DM/SHT/CAU                                                   |
| 5     | Sivasamy      | 56  |     |                               | 5   | 175 | 250  | 120 | 120          | 9.0           | M/C: H/F, V5 | 177 | 87 | 36 | 24 | 120 | 36 | 1.2        | 445          | T2DM/SHT/CAU/COPD/CP                                                   |
| 6     | Sivasamy      | 56  |     |                               | 5   | 175 | 250  | 120 | 120          | 9.0           | M/C: H/F, V5 | 177 | 87 | 36 | 24 | 120 | 36 | 1.2        | 445          | T2DM/SHT/CAU/COPD/CP                                                   |
| 7     | Sivasamy      | 56  |     |                               | 5   | 175 | 250  | 120 | 120          | 9.0           | M/C: H/F, V5 | 177 | 87 | 36 | 24 | 120 | 36 | 1.2        | 445          | T2DM/SHT/CAU/COPD/CP                                                   |
| 8     | Sivasamy      | 56  |     |                               | 5   | 175 | 250  | 120 | 120          | 9.0           | M/C: H/F, V5 | 177 | 87 | 36 | 24 | 120 | 36 | 1.2        | 445          | T2DM/SHT/CAU/COPD/CP                                                   |
| 9     | Sivasamy      | 56  |     |                               | 5   | 175 | 250  | 120 | 120          | 9.0           | M/C: H/F, V5 | 177 | 87 | 36 | 24 | 120 | 36 | 1.2        | 445          | T2DM/SHT/CAU/COPD/CP                                                   |
| 10    | Sivasamy      | 56  |     |                               | 5   | 175 | 250  | 120 | 120          | 9.0           | M/C: H/F, V5 | 177 | 87 | 36 | 24 | 120 | 36 | 1.2        | 445          | T2DM/SHT/CAU/COPD/CP                                                   |
| 11    | Sivasamy      | 56  |     |                               | 5   | 175 | 250  | 120 | 120          | 9.0           | M/C: H/F, V5 | 177 | 87 | 36 | 24 | 120 | 36 | 1.2        | 445          | T2DM/SHT/CAU/COPD/CP                                                   |
| 12    | Sivasamy      | 56  |     |                               | 5   | 175 | 250  | 120 | 120          | 9.0           | M/C: H/F, V5 | 177 | 87 | 36 | 24 | 120 | 36 | 1.2        | 445          | T2DM/SHT/CAU/COPD/CP                                                   |
| 13    | Sivasamy      | 56  |     |                               | 5   | 175 | 250  | 120 | 120          | 9.0           | M/C: H/F, V5 | 177 | 87 | 36 | 24 | 120 | 36 | 1.2        | 445          | T2DM/SHT/CAU/COPD/CP                                                   |
| 14    | Sivasamy      | 56  |     |                               | 5   | 175 | 250  | 120 | 120          | 9.0           | M/C: H/F, V5 | 177 | 87 | 36 | 24 | 120 | 36 | 1.2        | 445          | T2DM/SHT/CAU/COPD/CP                                                   |
| 15    | Sivasamy      | 56  |     |                               | 5   | 175 | 250  | 120 | 120          | 9.0           | M/C: H/F, V5 | 177 | 87 | 36 | 24 | 120 | 36 | 1.2        | 445          | T2DM/SHT/CAU/COPD/CP                                                   |
| 16    | Sivasamy      | 56  |     |                               | 5   | 175 | 250  | 120 | 120          | 9.0           | M/C: H/F, V5 | 177 | 87 | 36 | 24 | 120 | 36 | 1.2        | 445          | T2DM/SHT/CAU/COPD/CP                                                   |
| 17    | Sivasamy      | 56  |     |                               | 5   | 175 | 250  | 120 | 120          | 9.0           | M/C: H/F, V5 | 177 | 87 | 36 | 24 | 120 | 36 | 1.2        | 445          | T2DM/SHT/CAU/COPD/CP                                                   |
| 18    | Sivasamy      | 56  |     |                               | 5   | 175 | 250  | 120 | 120          | 9.0           | M/C: H/F, V5 | 177 | 87 | 36 | 24 | 120 | 36 | 1.2        | 445          | T2DM/SHT/CAU/COPD/CP                                                   |
| No. | Name       | Age | Sex | BP | HR | RR | ECG Abnormalities                                                                 | Echocardiographic Findings                      | Hematocrit | Blood Sugar | Creatinine | Diagnosis                                      | Management Strategy                | Score |
|-----|------------|-----|-----|----|----|----|----------------------------------------------------------------------------------|-----------------------------------------------|------------|-------------|------------|------------------------------------------------|-------------------------------------|--------|
| 39  | Kannagi    | 68  | 1   | 18 | 106| 142| No RWM, Normal LV function                                                        |                                               | 76         | 38          | 162        | 0.3 T2DM/CAD/ MALARIAL FEVER                     |                                     | 2      |
| 40  | Natarajan  | 69  | 2   | 18 | 137| 188| No RWM, Normal LV function                                                        |                                               | 92         | 32          | 142        | 1.3 T2DM/CAD/FEVER WITH ARTHRALGIA               |                                     | 2      |
| 41  | Krishnasri | 67  | 2   | 18 | 128| 175| Hypokinesia of RV septum, EF 45%                                                  | No RWMA, conc. LVW                             | 76         | 30          | 20         | 0.8 T2DM/CAD/ OLD RWM/ LVF                      |                                     | 2      |
| 42  | Krishnaraj | 70  | 2   | 19 | 191| 192| No RWMA, conc. LVW                                                               |                                               | 102        | 25          | 21         | 1 T2DM/CAD/ LATRAL WALL ISCHEMIA                |                                     | 2      |
| 43  | Muni       | 70  | 2   | 19 | 140| 195| No RWM, Normal LV function                                                        |                                               | 88         | 310         | 8.8        | 0.3 NSR. WNL                                    |                                     | 2      |
| 44  | Krishnasen | 73  | 2   | 21 | 132| 187| Low voltage complex with PPMW                                                    | Global hypokinesia of LV, EF 35%              | 84         | 28          | 20         | 1.1 T2DM/CAD/ISCHEMICAL DCMF/CCF                |                                     | 2      |
| 45  | Mathukannan| 73  | 2   | 21 | 146| 202| ST- v2-v5, Grade 1 DDI                                                           |                                               | 67         | 34          | 18         | 1.1 T2DM/SHT/UA/RECURRENT ANGINA               |                                     | 2      |
| 46  | Rajappa    | 74  | 2   | 21 | 133| 188| No RWM, Normal LV function                                                        |                                               | 102        | 26          | 23         | 1 T2DM/CAD/ENTERIC FEVER                       |                                     | 2      |
| 47  | Lalitha    | 75  | 2   | 22 | 123| 178| No RWM, Normal LV function                                                        |                                               | 88         | 38          | 20         | 0.8 T2DM/CAD/ENTERIC FEVER                     |                                     | 2      |
| 48  | Santhanan  | 76  | 2   | 23 | 126| 161| WNL                                                                                | Normal LV function                             | 76         | 46          | 18         | 0.9 T2DM/CAD/GERO                               |                                     | 2      |
| 49  | Henry      | 77  | 2   | 24 | 113| 188| Hypokinesia of Lateral basal segment, EF 49%                                      |                                               | 67         | 30          | 20         | 1.1 T2DM/CAD/UA                                |                                     | 2      |
| 50  | Remya bebum| 87  | 2   | 24 | 155| 210| No RWM, Normal LV function                                                        | Hypokinesia of inferior segment of LV, EF 28% | 82         | 32          | 18         | 1 T2DM/CAD/OLD I6M/DCMF/CCF                    |                                     | 2      |